OncoMatch/Clinical Trials/NCT06900647
Bortezomib Plus Cisplatin in Recurrent or Metastatic Breast Cancer
Is NCT06900647 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments for metastatic breast cancer.
Treatment: Bortezomib (B) · Cisplatin (CDDP) · Bortezomib (B) · Bortezomib (B) · Cisplatin (CDDP) — This a phase 1 study to evaluate the safety and preliminary efficacy of cisplatin combined with bortezomib in patients with recurrent or metastatic breast cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Lab requirements
Blood counts
anc ≥1.5×109/l, plt ≥75×109/l, hb ≥85g/l (no blood transfusion and blood products within 14 days, no use of g-csf and other hematopoietic stimulating factors for correction)
Kidney function
bun and cr ≤1×uln or endogenous creatinine clearance ≥50ml/min (cockcroft-gault formula)
Liver function
tbil <1.5×uln, alt, ast <2.5×uln, alt, ast <5×uln for patients with liver metastasis
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify